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Introduction
Autonomic nervous system significantly modulates activity of the atrial fibrillation (AF) triggers within the pulmonary veins (PVs). [1] Circumferential pulmonary vein isolation (CPVI) is the mainstay of catheter-ablation (CA) for paroxysmal AF (PAF), however the arrhythmia reoccurs in up to 30-50% of AF patients undergoing first CA. [2] CPVI may affect the cardiac autonomic nervous activity via (un)intentional injury of the left atrial (LA) parasympathetic ganglia (GP) in the proximity of PVs by radiofrequency (RF) current [1, 3] and the LA denervation is reported to significantly reduce AF recurrence rate after CPVI. [2, 4, 5] However, in the months following CA the processes of healing and re-innervation ensue, potentially influencing the procedure outcome. [3, 6, 7] A long-term pattern of CA-related cardiac denervation (and subsequent re-innervation) is underreported and currently available data are conflicting. [3, [6] [7] [8] We studied the pattern of longitudinal heart rate variability (HRV) changes (as a measure of cardiac denervation) after CPVI for PAF, and the relationship between the HRV change post-CPVI and long-term AF freedom.
Methods
Study population. Patient selection for this prospective single-centre study is presented in Figure S1 . Of 294 consecutive patients who underwent 445 RF-CA procedures for symptomatic/drug-resistant AF in the Clinical Centre of Serbia, between 2013 and 2016, we excluded those with persistent AF ablation, repeat AF ablation and/or substrate-based AF ablation (n = 195), those with history of previous slow-pathway or septal accessory pathway ablation and/or pace-maker implantation (n = 23), patients with history of heart failure, myocardial infarction and/or diabetes mellitus (n = 69), patients with > 20% of the 24-hour Holter-recording time spent in AF, frequent atrial/ventricular premature beats or artifacts (n = 49), and patients with ≤ 12 months post-CA follow-up (n = 9).
The study group consisted of 100 PAF patients with no significant structural heart disease who underwent their first CA-AF with CPVI stand-alone ablation strategy and were followed > 12 months post-procedure. PAF was defined as AF episode lasting > 30 sec, but < 7 days. [2] All AADs were discontinued ≥ 5 half-lives before CA (amiodarone was ceased > 3 months prior to CA). Prior to CA all patients underwent transthoracic echocardiography, cardiopulmonary exercise testing and 24-hour Holter-recording. The study has been approved by ethical board in our institution and all patients signed informed consent to participate in the study.
Ablation procedure. The CPVI-procedure in our hospital was previously described in details. [9] Briefly, after trans-septal puncture a 3D-map was created by the electro-anatomical mapping system (EnSite Velocity, St Jude, Minneapolis MN) and thereafter fused with segmented computed-tomography model of the LA. RF current was applied via externally irrigated 4-mm tip catheter (Therapy Cool-Flex, St Jude), with power of 30W and flow-rate of 17 ml/min. Local RF delivery was continued only until a > 80% reduction of atrial potential amplitude or for maximum of 30-40 sec and 40-60 sec at the posterior and anterior LA wall, respectively, whichever comes first. Ipsilateral PVs (left and right) were encircled in pairs with a circumferential ablation line deployed 5 mm from anterior and 15-20 mm from posterior aspects of their ostia, respectively. During the ablation, electrical activity of PVs was evaluated with circumferential mapping catheter. [9] In patients with history of typical atrial flutter, ablation of cavo-tricuspid isthmus was performed during the same session. [2] Post-ablation follow-up. AADs were routinely administered during the 3-month blanking period [2] and thereafter were discontinued in all patients. Post-ablation scheduled follow-up visits included physical examination, 12-lead ECG and 24-hour Holter-recording, at 1, 3, 6 months and afterwards every 6 months. AF recurrence was defined as any symptomatic/asymptomatic AF/AT (atrial tachycardia) episode of > 30 sec in duration. [2] Early recurrence of AF (ERAF) was defined as the atrial arrhythmia recurrence within the 3-month blanking period after CA, while the arrhythmia recurrence after 3 months following CA procedure was considered the late recurrence of AF (LRAF). [2] Patients experiencing ERAF during the blanking period were treated by cardioversion or rate control (but without early reablation), whereas those with documented LRAF after the blanking period were offered AAD readministration or repeat CA. [2] HRV analysis. In all patients, serial 3-channel 24-hour Holter-recordings (Del Mar Reynolds Medical Inc., Irvine, USA) with Impresario software for HRV analysis were obtained 1 day prior to ablation and 1 day, 1 month, 3 months and 6 months post-procedure and every 6 months thereafter. To provide high quality HRV measurements, all patients with any of the Holter-recordings showing AF episodes, ventricular/atrial premature beats, and/or artifacts for > 20% of the recording time were excluded from further analysis. 
RESULTS

Study population
The study group consisted of 100 patients (the mean [SD] age was 56.0 [11.2] years and 61 patients were male). Baseline patient characteristics are presented in Table 1 . The LRAF was documented in 17 patients between 3 and 12 months after CA, whereas in remaining 21 patients with LRAF the arrhythmia recurrence was recorded > 12 months post-CA.
During the first year post-CA, in 16 of 17 patients with LRAF AADs were re-instituted as monotherapy with propafenone (n = 1), sotalol (n = 1), verapamil (n = 1) or beta-blocker (n = 5), or as combination of amiodaron + beta-blocker (n = 3) or propafenone + beta-blocker (n = 5), and the remaining asymptomatic patient continued without AADs. CA was repeated in 18 out of 38 LRAF patients after mean (SD)16 (7) months. At repeat CA procedure, PV reconnections were identified in 16 of 18 patients (89%) with mean (SD) 2.4 (0.9) reconnected PVs per patient. PV reconnection rates (per patient) were as follows: left superior PV 10/18 (56%), left inferior PV 7/18 (39%), right superior PV 11/18 (61%) and right inferior PV 10/18 (56%).
No new adverse cardiovascular events such as sudden death, acute coronary syndrome or cardiac decompensation were observed during the study follow-up.
The 1-year HRV parameters changes post-ablation
There were no significant differences in HRV parameters at baseline (before CA) in patients with and without LRAF post-CA, except for SDNN (117 [IQR: 99-145] vs. 141 [IQR:
108-201], P = 0.04; see Table 2 ).
The 1-year post-ablation longitudinal HRV changes are summarized in Table 2 and Changes in HRV parameters during the first year post-CA between patients with and without LRAF is reported in Table 3 . The post-ablation reduction of several HRV parameters, i.e. ΔSDNN, ΔrMSSD, ΔSDSD and ΔpNN50, were significantly greater in LRAF-free compared with LRAF patients on the first post-ablation day and a significant difference in these HRV parameters between the LRAF-free and LRAF group was mostly preserved at 1, 3, 6 and 12 months post-procedure (Table 3 ). There were no significant differences in the post-ablation changes in other HRV parameters (i.e., the ΔHRV index, ΔMean RR interval, ΔMean HR and ΔLF/HF ratio) during the first year after CA between patients with and without the LRAF.
Among the LRAF patients (n = 38) there were no significant difference in HRV parameters change between the patients who underwent redo-CA procedure and those who treated only by AADs (SDNN before CA: 113 [IQR: 95, 150] vs. 122 [102, 143] , P = 0.5; reduction in SDNN at 3 months after CA: 5 [-5, 38] vs. 21 [2, 46] , P = 0.228). Tables 1-3 Table S1 ). A reduction in SDNN at 3 months post-CA (ΔSDNN(post-CA[3 m])) of ≤25 ms was associated with an increase in the prevalence of LRAF from 19.6% to 41.0% among ERAF-free patients (n=85), and from 71.4% to 100.0% among those who experienced ERAF (n=15), Figure   S2 .
Risk factors for LRAF
Univariate Cox analysis included all variables listed in
DISCUSSION
Our study of 100 PAF patients with no significant structural heart disease showed a "square root sign" pattern of longitudinal HRV parameters change during the first year after CPVI, with an immediate post-ablation HRV change indicating a significant parasympathetic attenuation and subsequent (partial) gradual returning of HRV indices over the following months toward pre-ablation level. The HRV markers of a significant reduction in parasympathetic tone persisted throughout the next 12 months post procedure in arrhythmia-free patients, whilst HRV parameters returned to baseline values within 3-6 months post-CPVI in patients with a late AF relapse. The SDNN change at the end of the 3-month blanking period post-CPVI was significantly associated with long-term AF recurrence.
Autonomic nervous system and AF. The LA contains four GPs, which are located at the epicardial aspect of the LA-PV junction. [1] The GPs includes both adrenergic and cholinergic nerve fibres that control the cardiac impulse formation and propagation, and therefore modulates the interplay between the PV triggers and LA substrate. [6] Thus, in younger patients with no structural heart disease, a vagal predomination promotes the afterdepolarization-related triggered PV activity, shortens the PV refractoriness and AF cycle length, resulting in AF inducibility/maintenance. [1, 11] Denervation and AF ablation outcome. GPs ablation led to vagal-response, e.g. bradycardia and hypotension, during RF current application and subsequently to non-inducibility of vagally-mediated AF. [1] Several studies reported significant change of HRV parameters after CPVI, indicating a significant parasympathetic withdrawal. [3, 6-8, 12, 13] The LA GPs are located close to the selected CPVI ablation trajectory [1] and therefore are commonly collaterally damaged during the ablation. [3, 6-8, 12, 13] Clinical studies showed significantly better AFfreedom post-CPVI among patients who exhibited more pronounced post-ablation change in HRV indices of parasympathetic denervation. [3, 6, 7, 12, 13] Consequently, the LA GPs become an important adjuvant ablation target on top of CPVI significantly improving the long-term CPVI outcome. [4, 5] Moreover, parasympathetic attenuation post-procedure had a supplemental and distinct effect on AF-freedom, irrespective of the late PVs reconnection. [7] However, healing of the RF-induced injury in the following weeks may be accompanied with re-innervation at the LA-PV junction, potentially influencing the long-term outcome after CPVI. [3, 7, 12, 13] Interestingly, the follow-up studies on persistency of denervation after AF ablation reported conflicting findings. [3, 6-8, 12, 13] Initially, it was suggested that denervation post-CPVI performed with conventional RF catheter is only a transient phenomenon followed by complete re-innervation at 6 months after ablation. [3, 8] However, a more recent study reported more persistent HRV changes during the first year after CPVI that was performed with more powerful irrigated RF ablation. [6] Again, the HRV reduction during the first year post-CPVI was significantly more striking and more persistent among AF-free patients than in those with recurrent AF. [6] In addition, long-term HRV change after CPVI was considerably different between patients with PAF and non-PAF. [6] Our study included a homogenous cohort of PAF patients with no significant structural heart disease who underwent stand-alone CPVI using irrigated RF catheters. Longitudinal HRV parameters change during the first year after CPVI depicted a characteristic "square root sign" pattern, consisting of significant early parasympathetic denervation post-CA and subsequent gradual re-innervation. Of importance, in spite of partial re-innervation after 3-6 months postablation, HRV markers of an overall sympatho-vagal balance (SDNN, SDSD, pNN50 and mean RR interval) and more specific HRV indices of parasympathetic activity (rMSSD and LF/HF ratio) were still significantly reduced at 1 year post-CPVI only in AF-free patients but not in those with the arrhythmia recurrence. Thus, in otherwise mostly healthy patients, persistently reduced HRV post-CPVI for PAF is a marker of better long-term AF control. However, since reduced HRV was previously recognized as a marker of adverse cardiovascular outcome in patients with history of myocardial infarction, heart failure or diabetes [14] it is questionable whether the post-CPVI denervation may affect the prognosis of patients undergoing AF ablation procedure if they develop significant cardio-metabolic co-morbidities in the future. Importantly, during the present study with median follow-up of almost 3 years post-ablation, our patients were free of new adverse cardiovascular events, such as sudden death, myocardial infarction or heart failure.
Prediction of CPVI outcome by peri-procedural HRV change assessment.
Previous studies identified HRV changes immediately post-CPVI as a predictor for AF recurrence. [3, 6-8, 12, 13, 15] Thus, post-ablation findings of high HF, low LF/HF ratio or LF/HF change > 0.26 were all independently associated with LRAF. [6, 7] However, interpretation of changes in the frequency-domain HRV parameters (i.e., HF and LF) is limited because their assessment depends considerably on respiration and measurement conditions. [10] On the other hand, timedomain HRV parameters measurement is more stable and reproducible in routine practice. [10] The SDNN absolute value at 3 months post-CPVI was previously identified as an independent risk factor for AF relapse. [8] However, our study further underlines the utility of peri-procedural SDNN analysis. First, we show that PAF patients with higher pre-ablation SDNN (as a measure of overall HRV) are the best candidates for CPVI. In addition, the SDNN reduction at 3 months post-CPVI of ≤ 25 ms was associated with a 2.5-fold increase in the probability for LRAF. Data on the 3-month post-ablation SDNN change are usually easily available by routine follow-up Holter-recording and may discriminate between the ERAF patients at increased and low risk for subsequent LRAF. Although ERAF is one of the strongest predictors of LRAF, in approximately 40-60% of the ERAF patients later AF episodes gradually subside with a resolution of CArelated LA inflammation. [2] Reliable prediction of the long-term CPVI success may optimize the selection of appropriate rhythm monitoring strategy, AADs use and anticoagulation treatment following the CA [16] .
Study limitations. Intermittent rhythm monitoring strategy by 24-hour Holter-recording
probably underestimated the recurrence rate post-CPVI. [2] AADs were routinely prescribed in all patients during the blanking period, thus possibly affecting the HRV parameters post-CA. [10] However, our post-ablation strategy was in line with the current guidelines. [2] The study population consisted of highly selected, relatively young and healthy PAF patients. Approximately 50% of the patients had hypertension and 5% had stable coronary artery disease, but patients with diabetes, history of MI and/or heart failure were excluded. Thus, transferability to the general AF population undergoing CA is limited. Notwithstanding that a strict patient selection to include only those with lone PAF would provide straightforward information, we believe that this patient selection minimized influence of cardiovascular disease(s) on HRV parameters and their changes in the first months post-ablation.
The exclusion of patients whose follow-up Holter recordings showed frequent aberrant beats could have introduced a selection bias. However, such approach ensured a good quality of HRV measurements. [10] The HRV analysis was limited to 12 months post-CPVI, whereas the re-innervation could have continued beyond first year post-ablation.
The association between HRV changes and AF-freedom post-CA may not necessarily be a causal relationship. Persistent changes in autonomic tone may be simple the result of a more effective (i.e. transmural) RF lesion, durable ablation line and therefore a better CA outcome.
CONCLUSIONS
Our study identified a "square root sign" pattern of HRV parameters change during the first year post-CPVI in PAF patients, with substantial parasympathetic withdrawal immediately post-ablation and its gradual recovery during the next months. Persistent HRV attenuation within first 12 months after AF ablation was a marker of long-term procedural success and AF-freedom.
A higher pre-ablation SDNN value potentially identified optimal candidates for CPVI, but this will require prospective validation. Conversely, a SDNN reduction of ≤ 25 ms at 3 months post-CPVI was a reliable predictor of subsequent AF relapse. Pre-procedural and follow-up HRV analyses could improve the prediction of LRAF in AF patients undergoing CPVI complementing other clinical predictors of LRAF, such as ERAF. Abbreviations - Tables 1, 2 ERAF, early recurrence of atrial fibrillation. Other abbreviationsfigure S1. 
